T. M. Willson, M. H. Lambert, and S. A. Kliewer, Peroxisome proliferator-activated receptor gamma and metabolic disease, Annu Rev Biochem, vol.70, pp.341-367, 2001.

B. Desvergne and W. Wahli, Peroxisome proliferator-activated receptors: nuclear control of metabolism, Endocr Rev, vol.20, pp.649-688, 1999.

T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, The PPARs: from orphan receptors to drug discovery, J Med Chem, vol.43, pp.527-550, 2000.

G. Ferry, V. Bruneau, P. Beauverger, M. Goussard, M. Rodriguez et al., Binding of prostaglandins to human PPARgamma: tool assessment and new natural ligands, Eur J Pharmacol, vol.417, pp.77-89, 2001.

J. M. Lehmann, L. B. Moore, T. A. Smith-oliver, W. O. Wilkison, T. M. Willson et al., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma

, J Biol Chem, vol.270, pp.12953-12956, 1995.

P. J. Brown, L. W. Stuart, K. P. Hurley, M. C. Lewis, D. A. Winegar et al., Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis, Bioorg Med Chem, vol.11, pp.1225-1227, 2001.

A. C. Li, K. K. Brown, M. J. Silvestre, T. M. Willson, W. Palinski et al., Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice, J Clin Invest, vol.106, pp.523-531, 2000.

K. K. Brown, B. R. Henke, S. G. Blanchard, J. E. Cobb, R. Mook et al., A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat, Diabetes, vol.48, pp.1415-1424, 1999.

W. R. Oliver, J. L. Shenk, M. R. Snaith, C. S. Russell, K. D. Plunket et al., A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport, Proc Natl Acad Sci U S A, vol.98, pp.5306-5311, 2001.

G. Chinetti, J. C. Fruchart, and B. Staels, Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation, Inflamm Res, vol.49, pp.497-505, 2000.

X. Y. Yang, L. H. Wang, T. Chen, D. R. Hodge, J. H. Resau et al., Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists: PPARgamma co-association with transcription factor NFAT, J Biol Chem, vol.275, pp.4541-4544, 2000.

P. Gervois, N. Vu-dac, R. Kleemann, M. Kockx, G. Dubois et al., Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta, J Biol Chem, vol.276, pp.33471-33477, 2001.

M. Fu, J. Zhang, X. Zhu, D. E. Myles, T. M. Willson et al., PPARgamma inhibits TGFbeta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3, J Biol Chem, vol.276, pp.45888-45894, 2001.

T. Lemberger, R. Saladin, M. Vazquez, F. Assimacopoulos, B. Staels et al., Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm, J Biol Chem, vol.271, pp.1764-1769, 1996.

T. C. Leone, C. J. Weinheimer, and D. P. Kelly, A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders, Proc Natl Acad Sci U S A, vol.96, pp.7473-7478, 1999.

S. Kersten, J. Seydoux, J. M. Peters, F. J. Gonzalez, B. Desvergne et al., Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting, J Clin Invest, vol.103, pp.1489-1498, 1999.

H. M. Guardiola-diaz, S. Rehnmark, N. Usuda, T. Albrektsen, D. Feltkamp et al., Rat peroxisome proliferator-activated receptors and brown adipose tissue function during cold acclimatization, J Biol Chem, vol.274, pp.23368-23377, 1999.

A. J. Vidal-puig, R. V. Considine, M. Jimenez-linan, A. Werman, W. J. Pories et al., Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids, J Clin Invest, vol.99, pp.2416-2422, 1997.

T. Lemberger, B. Staels, R. Saladin, B. Desvergne, J. Auwerx et al., Regulation of the peroxisome proliferator-activated receptor alpha gene by glucocorticoids, J Biol Chem, vol.269, pp.24527-24530, 1994.

H. H. Steineger, H. N. Sorensen, J. D. Tugwood, S. Skrede, O. Spydevold et al., Dexamethasone and insulin demonstrate marked and opposite regulation of the steady-state mRNA level of the peroxisomal proliferator-activated receptor (PPAR) in hepatic cells: hormonal modulation of fatty-acid-induced transcription, Eur J Biochem, vol.225, pp.967-974, 1994.

J. T. Huang, J. S. Welch, M. Ricote, C. J. Binder, T. M. Willson et al., Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase, Nature, vol.400, pp.378-382, 1999.

S. L. Pearson, M. A. Cawthorne, J. C. Clapham, S. J. Dunmore, S. D. Holmes et al., The thiazolidinedione insulin sensitizer, BRL 49653, increases the expression of PPAR-gamma and aP2 in adipose tissue of high-fat-fed rats, Biochem Biophys Res Commun, vol.229, pp.752-757, 1996.

A. Valmaseda, M. C. Carmona, M. J. Barbera, O. Vinas, T. Mampel et al., Opposite regulation of PPAR-alpha and -gamma gene expression by both their ligands and retinoic acid in brown adipocytes, Mol Cell Endocrinol, vol.154, pp.101-109, 1999.

S. Hauser, G. Adelmant, P. Sarraf, H. M. Wright, E. Mueller et al., Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation, J Biol Chem, vol.275, pp.18527-18533, 2000.

M. Hirotani, T. Tsukamoto, J. Bourdeaux, H. Sadano, and T. Osumi, Stabilization of peroxisome proliferator-activated receptor alpha by the ligand, Biochem Biophys Res Commun, vol.288, pp.106-110, 2001.

C. Blanquart, O. Barbier, J. C. Fruchart, B. Staels, and C. Glineur, Peroxisome proliferator-activated receptor alpha turnover by the ubiquitinproteasome system controls the ligand-induced expression level of its target genes, J Biol Chem

I. Pineda-torra, G. Chinetti, C. Duval, J. C. Fruchart, and B. Staels, Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice, Curr Opin Lipidol, vol.12, pp.245-254, 2001.

J. B. Hansen, H. Zhang, T. H. Rasmussen, R. K. Petersen, E. N. Flindt et al., Peroxisome proliferator-activated receptor deltamediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling, J Biol Chem, vol.276, pp.3175-3182, 2001.

E. C. Person, L. L. Waite, R. N. Taylor, and T. S. Scanlan, Albumin regulates induction of peroxisome proliferator-activated receptor-gamma (PPARgamma) by 15-deoxy-delta(12-14)-prostaglandin J(2) in vitro and may be an important regulator of PPARgamma function in vivo. Endocrinology, vol.142, pp.551-556, 2001.

C. Wolfrum, C. M. Borrmann, T. Borchers, and F. Spener, Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha-and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus, Proc Natl Acad Sci U S A, vol.98, pp.2323-2328, 2001.

R. Mukherjee, P. A. Hoener, L. Jow, J. Bilakovics, K. Klausing et al., A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes, Mol Endocrinol, vol.14, pp.1425-1433, 2000.

S. Rocchi, F. Picard, J. Vamecq, L. Gelman, N. Potier et al., A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity, Mol Cell, vol.8, pp.737-747, 2001.

J. M. Olefsky, Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists, J Clin Invest, vol.106, pp.467-472, 2000.

B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf et al., Mechanism of action of fibrates on lipid and lipoprotein metabolism, Circulation, vol.98, pp.2088-2093, 1998.

K. Motojima, P. Passilly, J. M. Peters, F. J. Gonzalez, and N. Latruffe, Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissueand inducer-specific manner, J Biol Chem, vol.273, pp.16710-16714, 1998.

G. Martin, K. Schoonjans, A. M. Lefebvre, B. Staels, and J. Auwerx, Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators, J Biol Chem, vol.272, pp.28210-28217, 1997.

I. Issemann, R. Prince, J. Tugwood, and S. Green, A role for fatty acids and liver fatty acid binding protein in peroxisome proliferation?, Biochem Soc Trans, vol.20, pp.824-827, 1992.

H. Poirier, I. Niot, M. C. Monnot, O. Braissant, C. Meunier-durmort et al., Differential involvement of peroxisome-proliferator-activated receptors alpha and delta in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acidbinding protein in the liver and the small intestine, Biochem J, vol.355, pp.481-488, 2001.

K. Schoonjans, M. Watanabe, H. Suzuki, A. Mahfoudi, G. Krey et al., Induction of the acylcoenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter, J Biol Chem, vol.270, pp.19269-19276, 1995.

M. Guerre-millo, P. Gervois, E. Raspe, L. Madsen, P. Poulain et al., Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity, J Biol Chem, vol.275, pp.16638-16642, 2000.

C. Mascaro, E. Acosta, J. A. Ortiz, P. F. Marrero, F. G. Hegardt et al., Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor, J Biol Chem, vol.273, pp.8560-8563, 1998.

J. M. Brandt, F. Djouadi, and D. P. Kelly, Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha, J Biol Chem, vol.273, pp.23786-23792, 1998.

J. F. Louet, F. Chatelain, J. F. Decaux, E. A. Park, C. Kohl et al., Long-chain fatty acids regulate liver carnitine palmitoyltransferase I gene (L-CPT I) expression through a peroxisomeproliferator-activated receptor alpha (PPARalpha)-independent pathway, Biochem J, vol.354, pp.189-197, 2001.

T. Aoyama, J. M. Peters, N. Iritani, T. Nakajima, K. Furihata et al., Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha), J Biol Chem, vol.273, pp.5678-5684, 1998.

F. Djouadi, C. J. Weinheimer, J. E. Saffitz, C. Pitchford, J. Bastin et al., A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alphadeficient mice, J Clin Invest, vol.102, pp.1083-1091, 1998.

J. C. Rodriguez, G. Gil-gomez, F. G. Hegardt, and D. Haro, Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids, J Biol Chem, vol.269, pp.18767-18772, 1994.

J. W. Lawrence, Y. Li, S. Chen, J. G. Deluca, J. P. Berger et al., Differential gene regulation in human vs rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR)alpha: PPARalpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression, J Biol Chem, vol.276, pp.31521-31527, 2001.

B. Staels, N. Vu-dac, V. A. Kosykh, R. Saladin, J. C. Fruchart et al., Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase: a potential mechanism for the hypolipidemic action of fibrates, J Clin Invest, vol.95, pp.705-712, 1995.

R. Hertz, J. Bishara-shieban, and J. Bar-tana, Mode of action of peroxisome proliferators as hypolipidemic drugs: suppression of apolipoprotein C-III, J Biol Chem, vol.270, pp.13470-13475, 1995.

K. Schoonjans, J. Peinado-onsurbe, A. M. Lefebvre, R. A. Heyman, M. Briggs et al., PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene, EMBO J, vol.15, pp.5336-5348, 1996.

K. Tordjman, C. Bernal-mizrachi, L. Zemany, S. Weng, C. Feng et al., PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice, J Clin Invest, vol.107, pp.1025-1034, 2001.

J. M. Way, W. W. Harrington, K. K. Brown, W. K. Gottschalk, S. S. Sundseth et al., Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues, Endocrinology, vol.142, pp.1269-1277, 2001.

R. W. Stevenson, N. J. Hutson, M. N. Krupp, R. A. Volkmann, G. F. Holland et al., Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice, Diabetes, vol.39, pp.1218-1227, 1990.

J. W. Kemnitz, D. F. Elson, E. B. Roecker, S. T. Baum, R. N. Bergman et al., Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys, Diabetes, vol.43, pp.204-211, 1994.

A. M. Lefebvre, J. Peinado-onsurbe, I. Leitersdorf, M. R. Briggs, J. R. Paterniti et al., Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates, Arterioscler Thromb Vasc Biol, vol.17, pp.1756-1764, 1997.

H. Castelein, T. Gulick, P. E. Declercq, G. P. Mannaerts, D. D. Moore et al., The peroxisome proliferator activated receptor regulates malic enzyme gene expression, J Biol Chem, vol.269, pp.26754-26758, 1994.

G. Chinetti, F. G. Gbaguidi, S. Griglio, Z. Mallat, M. Antonucci et al., CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors, Circulation, vol.101, pp.2411-2417, 2000.

G. Chinetti, S. Lestavel, V. Bocher, A. T. Remaley, B. Neve et al., PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway, Nat Med, vol.7, pp.53-58, 2001.

A. Chawla, W. A. Boisvert, C. H. Lee, B. A. Laffitte, Y. Barak et al., A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis, Mol Cell, vol.7, pp.161-171, 2001.

N. Vu-dac, K. Schoonjans, B. Laine, J. C. Fruchart, J. Auwerx et al., Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element, J Biol Chem, vol.269, pp.31012-31018, 1994.

N. Vu-dac, K. Schoonjans, V. Kosykh, J. Dallongeville, J. C. Fruchart et al., Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor, J Clin Invest, vol.96, pp.741-750, 1995.

C. H. Warden, C. C. Hedrick, J. H. Qiao, L. W. Castellani, and A. J. Lusis, Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II, Science, vol.261, pp.469-472, 1993.

A. Tailleux, M. Bouly, G. Luc, G. Castro, J. M. Caillaud et al., Decreased susceptibility to diet-induced atherosclerosis in human apolipoprotein A-II transgenic mice, Arterioscler Thromb Vasc Biol, vol.20, pp.2453-2458, 2000.

M. D. Leibowitz, C. Fievet, N. Hennuyer, J. Peinado-onsurbe, H. Duez et al., Activation of PPARdelta alters lipid metabolism in db/db mice, FEBS Lett, vol.473, pp.333-336, 2000.

M. Bouly, D. Masson, B. Gross, X. C. Jiang, C. Fievet et al., Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate, J Biol Chem, vol.276, pp.25841-25847, 2001.

X. C. Jiang, S. Qin, M. Lin, M. Schneider, A. R. Tall et al., Phospholipid transfer protein (PLTP) deficiency represents an anti-oxidant state in mice, Circulation, vol.104, p.1118, 2001.

B. Staels, A. Van-tol, G. Skretting, and J. Auwerx, Lecithin:cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates, J Lipid Res, vol.33, pp.727-735, 1992.

K. A. Tobin, H. H. Steineger, S. Alberti, O. Spydevold, J. Auwerx et al., Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-alpha, Mol Endocrinol, vol.14, pp.741-752, 2000.

J. Y. Chiang, R. Kimmel, and D. Stroup, Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha), Gene, vol.262, pp.257-265, 2001.

D. Stahlberg, E. Reihner, M. Rudling, L. Berglund, K. Einarsson et al., Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: reduced activity of cholesterol 7 alpha-hydroxylase, Hepatology, vol.21, pp.1025-1030, 1995.

M. Bertolotti, M. Concari, P. Loria, N. Abate, A. Pinetti et al., Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7 alpha-hydroxylation in humans, Arterioscler Thromb Vasc Biol, vol.15, pp.1064-1069, 1995.

S. M. Post, H. Duez, P. P. Gervois, B. Staels, F. Kuipers et al., Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression, Arterioscler Thromb Vasc Biol, vol.21, pp.1840-1845, 2001.

S. K. Cheema and L. B. Agellon, The murine and human cholesterol 7alpha-hydroxylase gene promoters are differentially responsive to regulation by fatty acids mediated via peroxisome proliferator-activated receptor alpha, J Biol Chem, vol.275, pp.12530-12536, 2000.

M. C. Hunt, Y. Z. Yang, G. Eggertsen, C. M. Carneheim, M. Gafvels et al., The peroxisome proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis, J Biol Chem, vol.275, pp.28947-28953, 2000.

, DAIS: effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study, Lancet, vol.357, pp.905-910, 2001.

C. G. Ericsson, A. Hamsten, J. Nilsson, L. Grip, B. Svane et al., Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients, Lancet, vol.347, pp.849-853, 1996.

M. H. Frick, M. Syvanne, M. S. Nieminen, H. Kauma, S. Majahalme et al., Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol: Lipid Coronary Angiography Trial (LOCAT) Study Group, Circulation, vol.96, pp.2137-2143, 1997.

R. E. Law, W. P. Meehan, X. P. Xi, K. Graf, D. A. Wuthrich et al., Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia, J Clin Invest, vol.98, pp.1897-1905, 1996.

H. Satoh, K. Tsukamoto, Y. Hashimoto, N. Hashimoto, M. Togo et al., Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function, Biochem Biophys Res Commun, vol.254, pp.757-763, 1999.

P. Delerive, F. Martin-nizard, G. Chinetti, F. Trottein, J. C. Fruchart et al., Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway, Circ Res, vol.85, pp.394-402, 1999.

K. Murao, H. Imachi, A. Momoi, Y. Sayo, H. Hosokawa et al., Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells, FEBS Lett, vol.454, pp.27-30, 1999.

H. Lee, W. Shi, P. Tontonoz, S. Wang, G. Subbanagounder et al., Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells, Circ Res, vol.87, pp.516-521, 2000.

V. Pasceri, J. Chang, J. T. Willerson, and E. T. Yeh, Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs, Circulation, vol.103, pp.2531-2534, 2001.

N. Marx, F. Mach, A. Sauty, J. H. Leung, M. N. Sarafi et al., Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells, J Immunol, vol.164, pp.6503-6508, 2000.

D. C. Jones, X. Ding, and R. A. Daynes, Nuclear receptor PPARalpha is expressed in resting murine lymphocytes: the PPARalpha in T and B lymphocytes is both transactivation and transrepression competent, J Biol Chem, vol.277, pp.6838-6845, 2002.

P. Wang, P. O. Anderson, S. Chen, K. M. Paulsson, H. O. Sjogren et al., Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands, Int Immunopharmacol, vol.1, pp.803-812, 2001.

K. H. Han and O. Quehenberger, Ligands for peroxisome proliferator-activated receptor inhibit monocyte CCR2 expression stimulated by plasma lipoproteins, Trends Cardiovasc Med, vol.10, pp.209-216, 2000.

N. Marx, G. K. Sukhova, T. Collins, P. Libby, and J. Plutzky, PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells, Circulation, vol.99, pp.3125-3131, 1999.

S. M. Jackson, F. Parhami, X. P. Xi, J. A. Berliner, W. A. Hsueh et al., Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction, Arterioscler Thromb Vasc Biol, vol.19, pp.2094-2104, 1999.

V. Pasceri, H. D. Wu, J. T. Willerson, and E. T. Yeh, Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators, Circulation, vol.101, pp.235-238, 2000.

K. J. Moore, E. D. Rosen, M. L. Fitzgerald, F. Randow, L. P. Andersson et al., The role of PPAR-gamma in macrophage differentiation and cholesterol uptake, Nat Med, vol.7, pp.41-47, 2001.

A. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz et al., PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation, Nat Med, vol.7, pp.48-52, 2001.

H. Vosper, L. Patel, T. L. Graham, G. A. Khoudoli, A. Hill et al., The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages, J Biol Chem, vol.276, pp.44258-44265, 2001.

A. R. Collins, W. P. Meehan, U. Kintscher, S. Jackson, S. Wakino et al., Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice, Arterioscler Thromb Vasc Biol, vol.21, pp.365-371, 2001.

Z. Chen, S. Ishibashi, S. Perrey, J. Osuga, T. Gotoda et al., Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL, Arterioscler Thromb Vasc Biol, vol.21, pp.372-377, 2001.

V. R. Babaev, A. S. Major, T. Zhu, I. Hiroyuki, D. E. Dove et al., Macrophage expression of PPAR-alpha inhibits atherosclerotic lesion formation in LDL-receptor deficient mice, Circulation, vol.104, pp.45-46, 2001.

P. Delerive, D. Bosscher, K. Besnard, S. , V. Berghe et al., Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1, J Biol Chem, vol.274, pp.32048-32054, 1999.

P. Delerive, J. C. Fruchart, and B. Staels, Peroxisome proliferator-activated receptors in inflammation control, J Endocrinol, vol.169, pp.453-459, 2001.

M. Ricote, J. T. Huang, J. S. Welch, and C. K. Glass, The peroxisome proliferatoractivated receptor(PPARgamma) as a regulator of monocyte/macrophage function, J Leukoc Biol, vol.66, pp.733-739, 1999.

Y. Azuma, M. Shinohara, P. L. Wang, and K. Ohura, 15-Deoxy-delta(12,14)-prostaglandin J(2) inhibits IL-10 and IL-12 production by macrophages, Biochem Biophys Res Commun, vol.283, pp.344-346, 2001.

B. Staels, W. Koenig, A. Habib, R. Merval, M. Lebret et al., Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators, Nature, vol.393, pp.790-793, 1998.

B. P. Neve, D. Corseaux, G. Chinetti, C. Zawadzki, J. C. Fruchart et al., PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages, Circulation, vol.103, pp.207-212, 2001.

N. Marx, N. Mackman, U. Schonbeck, N. Yilmaz, V. V. Hombach et al., PPARalpha activators inhibit tissue factor expression and activity in human monocytes, Circulation, vol.103, pp.213-219, 2001.

C. Couturier, A. Brouillet, C. Couriaud, K. Koumanov, G. Bereziat et al., Interleukin 1beta induces type II-secreted phospholipase A(2) gene in vascular smooth muscle cells by a nuclear factor kappaB and peroxisome proliferator-activated receptor-mediated process, J Biol Chem, vol.274, pp.23085-23093, 1999.

J. Neuzil, J. M. Upston, P. K. Witting, K. F. Scott, and R. Stocker, Secretory phospholipase A2 and lipoprotein lipase enhance 15-lipoxygenaseinduced enzymic and nonenzymic lipid peroxidation in low-density lipoproteins, Biochemistry, vol.37, pp.9203-9210, 1998.

P. R. Devchand, H. Keller, J. M. Peters, M. Vazquez, F. J. Gonzalez et al., The PPARalpha-leukotriene B4 pathway to inflammation control, Nature, vol.384, pp.39-43, 1996.

D. L. Fuell, M. I. Freed, A. S. Greenberg, S. Haffner, and H. Chen, The effect of treatment with rosiglitazone on C-reactive protein and interleukin-6 in patients with type 2 diabetes, Diabetes, vol.50, 2001.

N. Marx, G. Sukhova, C. Murphy, P. Libby, and J. Plutzky, Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro, Am J Pathol, vol.153, pp.17-23, 1998.

R. R. Pauly, A. Passaniti, C. Bilato, R. Monticone, L. Cheng et al., Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation, Circ Res, vol.75, pp.41-54, 1994.

S. Goetze, U. Kintscher, S. Kim, W. P. Meehan, K. Kaneshiro et al., Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration, J Cardiovasc Pharmacol, vol.38, pp.909-921, 2001.

Y. Ikeda, A. Sugawara, Y. Taniyama, A. Uruno, K. Igarashi et al., Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2, J Biol Chem, vol.275, pp.33142-33150, 2000.

A. Sugawara, K. Takeuchi, A. Uruno, Y. Ikeda, S. Arima et al., Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes, Hypertens Res, vol.24, pp.229-233, 2001.

D. Hourton, P. Delerive, J. Stankova, B. Staels, M. J. Chapman et al., Oxidized low-density lipoprotein and peroxisome-proliferator-activated receptor alpha down-regulate platelet-activating-factor receptor expression in human macrophages, Biochem J, vol.354, pp.225-232, 2001.

P. N. Durrington, M. I. Mackness, D. Bhatnagar, K. Julier, H. Prais et al., Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia, Atherosclerosis, vol.138, pp.217-225, 1998.

K. Kato, D. Yamada, S. Midorikawa, W. Sato, and T. Watanabe, Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus, Metabolism, vol.49, pp.662-665, 2000.

K. Kato, H. Satoh, Y. Endo, D. Yamada, S. Midorikawa et al., Thiazolidinediones downregulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelial function, Biochem Biophys Res Commun, vol.258, pp.431-435, 1999.

N. Marx, T. Bourcier, G. K. Sukhova, P. Libby, and J. Plutzky, PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease, Arterioscler Thromb Vasc Biol, vol.19, pp.546-551, 1999.

W. Martinet and M. M. Kockx, Apoptosis in atherosclerosis: focus on oxidized lipids and inflammation, Curr Opin Lipidol, vol.12, pp.535-541, 2001.

G. Chinetti, S. Griglio, M. Antonucci, I. P. Torra, P. Delerive et al., Activation of proliferatoractivated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages, J Biol Chem, vol.273, pp.25573-25580, 1998.

S. Wakino, U. Kintscher, Z. Liu, S. Kim, F. Yin et al., PPARgamma ligands inhibit mitogenic induction of p21Cip1 by modulating the PKC pathway in vascular smooth muscle cells, J Biol Chem, vol.276, pp.47650-47657, 2001.

L. Patel, I. Pass, P. Coxon, C. P. Downes, S. A. Smith et al., Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN, Curr Biol, vol.11, pp.764-768, 2001.

H. B. Rubins, S. J. Robins, D. Collins, C. L. Fye, J. W. Anderson et al., Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, N Engl J Med, vol.341, pp.410-418, 1999.

M. H. Frick, O. Elo, K. Haapa, O. P. Heinonen, P. Heinsalmi et al., Helsinki Heart Study. primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease, N Engl J Med, vol.317, pp.1237-1245, 1987.

R. S. Elkeles, J. R. Diamond, C. Poulter, S. Dhanjil, A. N. Nicolaides et al., Cardiovascular outcomes in type 2 diabetes: a double-blind placebo-controlled study of bezafibrate: the, SENDCAP) Study. Diabetes Care, vol.21, pp.641-648, 1998.

M. S. Kipnes, A. Krosnick, M. S. Rendell, J. W. Egan, A. L. Mathisen et al., Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study, Am J Med, vol.111, pp.10-17, 2001.

F. Kaplan, K. Al-majali, and D. J. Betteridge, PPARS, insulin resistance and type 2 diabetes, J Cardiovasc Risk, vol.8, pp.211-217, 2001.

J. Minamikawa, S. Tanaka, M. Yamauchi, D. Inoue, and H. Koshiyama, Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes, J Clin Endocrinol Metab, vol.83, pp.1818-1820, 1998.

C. G. Gegick and M. D. Altheimer, Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice, Endocr Pract, vol.7, pp.162-169, 2001.

U. Smith, Pioglitazone: mechanism of action, Int J Clin Pract Suppl, vol.121, pp.13-18, 2001.

E. A. Gale, Lessons from the glitazones: a story of drug development, Lancet, vol.357, pp.1870-1875, 2001.